Perspective Therapeutics reports 2Q26 net loss $26.8M; advances VMT-α-NET toward Phase 3

Perspective Therapeutics, Inc.

Net loss $26.8M ($0.22/share) vs $21.5M ($0.29) in 2Q25; R&D expenses $21.5M, up from $16.6M.
Cash and investments $237M at 6/30/26, up from $145M at 12/31/25; runway into late 2027.
VMT-α-NET: 76 NET patients treated; Phase 3 planned at cumulative 20 mCi dose; site activation targeted year-end 2026.
VMT01: 27 patients; 2 partial responses at 3.0 mCi monotherapy; nivolumab combo cohort progressing.
Appointed Paul Lyne, Ph.D. as Chief Science Officer in July 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.